Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA), the most common chronic rheumatologic condition in childhood, remains a cause of significant morbidity, particularly in those with spondyloarthropathy, including psoriatic arthritis (PsA) and enthesitis-related arthritis (ERA). While secukinumab was recently appr...
Main Authors: | Meghan Corrigan Nelson DO, Cynthia K. Manos MD, MSCE |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-09-01
|
Series: | Journal of Investigative Medicine High Impact Case Reports |
Online Access: | https://doi.org/10.1177/23247096231200403 |
Similar Items
-
Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide
by: Tania Caroline Monteiro de Castro, et al. -
Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis
by: Mario Abinun, et al.
Published: (2016-10-01) -
Talus Arthritis Pattern in Juvenile Idiopathic Arthritis (JIA)
by: Mohammad Alkhreisat MD, et al.
Published: (2019-10-01) -
EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-01-01) -
EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-03-01)